Jon Krell is a Senior Clinical Lecturer in Medical Oncology with a clinical focus on the systemic management of patients with gynaecological malignancies. He also has a specialist clinical interest in cancer genetics and hereditary malignancies, particularly those involving the BRCA gene and other genetic mutations. He qualified in medicine at Leeds University Medical School, where he also gained a first class honours degree in Pharmacology. After completion of junior doctor posts at St. James’ Hospital in Leeds and Guys and St. Thomas’ Hospitals in London, he undertook his training in oncology at Charing Cross and Hammersmith Hospitals in London.
Dr Krell’s PhD research was funded by the Medical Research Council and investigated the interplay between genetic mutations, DNA damage and the response to cancer therapeutics. His ongoing research programme focuses on cancer genetics, polygenic risk and the interface between germline and somatic mutations, especially related to TP53 and BRCA. He also has a strong interest in the role of tumour and circulating small non-coding RNAs as diagnostic, prognostic and predictive biomarkers and as therapeutic modalities. This focuses on the areas of gynaecological and pancreatic malignancies and there is a strong translational research element to his work. He is a prominent member of the translational research team within the Ovarian Cancer Action Centre and Cancer Research UK centre at Imperial College that aims to overcome resistance to current anti-cancer agents in ovarian cancer. Current investigator-led trials include the OCA-funded PROGRESS study that aims to determine the feasibility of using a cancer risk algorithm to guide the personalisation of cancer screening and prevention programmes, and a BRC funded collaborative trial with the ICR investigating the role of Mainstreaming genetic testing in the cancer clinic.
Dr Krell has published over 100 peer-reviewed papers in journals such as the Lancet Oncology, Genome Research, The Journal of Clinical Oncology and Blood and regularly presents new data from his research at major national and international conferences.
et al., 2023, How does the polymer architecture and position of cationic charges affect cell viability?, Polymer Chemistry, Vol:14, ISSN:1759-9954, Pages:303-317
et al., 2022, A randomised, multi-centre phase II trial of weekly paclitaxel and vistusertib in platinum-resistant ovarian high-grade serous carcinoma: OCTOPUS Arm 1, Jama Oncology, ISSN:2374-2445
et al., 2022, Polymorphic microbes: a new emerging hallmark of cancer, Trends in Microbiology, Vol:30, ISSN:0966-842X, Pages:1131-1134
et al., 2022, From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK Oncology Drug Approval following Brexit, The Lancet Oncology, ISSN:1213-9432
et al., 2022, 627 Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy, SITC 37th Annual Meeting (SITC 2022) Abstracts, BMJ Publishing Group Ltd